Viridian Therapeutics, Inc. (VRDN) has a negative trailing P/E of -3.7, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 8.3 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -27.05%, forward earnings yield 12.11%. PEG 0.11 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 56/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -4.3 | 0.26 | -166.30 | 16.25 | - |
| 2017 | -7.6 | -0.43 | 5.21 | 50.14 | - |
| 2018 | -2.7 | 0.14 | 1.75 | 10.70 | - |
| 2019 | -0.4 | -0.02 | 0.95 | 3.37 | - |
| 2020 | -0.5 | -0.01 | 0.49 | 55.73 | - |
| 2021 | -3.0 | 0.04 | 1.26 | 79.53 | - |
| 2022 | -7.2 | 0.17 | 2.37 | 528.93 | - |
| 2023 | -4.1 | -0.11 | 2.21 | 3,104.38 | - |
| 2024 | -4.8 | 0.19 | 1.94 | 4,309.19 | - |
| 2025 | -7.7 | 0.46 | 3.65 | 37.25 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-17.57 | $3.34M | $-12.67M | -379.8% |
| 2017 | $-20.66 | $4M | $-26.51M | -662.3% |
| 2018 | $-16.57 | $8.39M | $-32.7M | -390% |
| 2019 | $-20.31 | $4.46M | $-42.42M | -950.9% |
| 2020 | $-31.20 | $1.05M | $-110.98M | -10569.9% |
| 2021 | $-6.66 | $2.96M | $-79.42M | -2680.3% |
| 2022 | $-3.91 | $1.77M | $-125.44M | -7079.2% |
| 2023 | $-5.31 | $314K | $-237.73M | -75711.5% |
| 2024 | $-3.98 | $302K | $-269.95M | -89387.1% |
| 2025 | $-3.32 | $70.85M | $-342.6M | -483.6% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-3.91 | $-5.22 – $-3.00 | $71.47M | $12.12M – $166.54M | 12 |
| 2027 | $-1.97 | $-3.66 – $-0.75 | $310.42M | $206.7M – $576.08M | 12 |
| 2028 | $0.94 | $-7.07 – $9.54 | $695.76M | $342.3M – $1.47B | 11 |
| 2029 | $3.22 | $1.09 – $7.89 | $1.03B | $505.74M – $2.17B | 4 |
| 2030 | $4.81 | $1.63 – $11.77 | $1.32B | $647.11M – $2.78B | 4 |
